Evidence map›Paper›PMID 41258625›Full record

Observational studyAdvances in therapy2026

Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS Studies.

Lana D Melendres-Groves, Richard N Channick, Kelly M Chin, Vallerie V McLaughlin, Gwen MacDonald, Nicolas Martin, Rose Ong, Marinella Sandros, Nick H Kim

2 registry-linked trialsAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02126943 completednot on this map

US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice

TypeobservationalSponsorActelionRan2014 to 2020Enrolled2,686ConditionsPulmonary Arterial HypertensionArmsOpsumit (macitentan)
NCT03197688 completednot on this map

Multicenter, Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

TypeobservationalSponsorActelionRan2017 to 2018Enrolled2,200ConditionsPulmonary Arterial HypertensionArmsNotapplicable
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lana D Melendres-GrovesDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA. LMelendres@salud.unm.edu.ORCID 0009-0001-7964-8322
Richard N ChannickDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Kelly M ChinUT Southwestern Medical Center, Dallas, TX, USA.
Vallerie V McLaughlinUniversity of Michigan, Ann Arbor, MI, USA.
Gwen MacDonaldJohnson & Johnson, Allschwil, Switzerland.
Nicolas MartinJohnson & Johnson, Allschwil, Switzerland.
Rose OngJohnson & Johnson, Allschwil, Switzerland.
Marinella SandrosJohnson & Johnson, Titusville, NJ, USA.
Nick H KimUniversity of California San Diego, La Jolla, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRacial and ethnic minorities are underrepresented in most pulmonary arterial hypertension (PAH) studies. The OPsumit® Users (OPUS) and Opsumit® Historical Users cohort (OrPHeUS) studies captured real-world data for US patients newly initiating macitentan. Patient characteristics, treatment patterns, and outcomes in the combined OPUS/OrPHeUS dataset are described by race (Black/African American or White) and by ethnicity (Hispanic/Latino or not Hispanic/Latino).

methodsOPUS was a prospective, observational drug registry (Apr 2014-Jun 2020; NCT02126943). OrPHeUS was a medical chart review (Oct 2013-Mar 2017; NCT03197688). All analyses are descriptive.

resultsThe OPUS/OrPHeUS PAH follow-up set comprised 4626 patients: 752/4589 (16.4%) Black/African American, 3484/4589 (75.9%) White; 517/4609 (11.2%) Hispanic/Latino, 3907/4609 (84.8%) not Hispanic/Latino. Black/African American versus White patients were slightly younger at diagnosis (median [Q1,Q3] 57 [47,66]/61 [48,71] years), with more connective tissue disease-associated PAH (33.0%/25.1%). Treatment patterns between races were similar. For Black/African American versus White patients, 1-year Kaplan-Meier estimates (95% confidence limit [CL]) for survival were 89.6% (86.8,91.8)/90.3% (89.1,91.4); freedom from all-cause hospitalization was 52.5% (48.4,56.4)/61.2% (59.4,63.0). Hispanic/Latino versus not Hispanic/Latino patients were younger at diagnosis (median [Q1,Q3] 53 [39,63]/60 [48,70] years) with more congenital heart disease-associated PAH (12.8%/5.3%) and longer median (95% CL) time from diagnosis to first, double, and triple combination PAH therapy (2.8 [2.3,3.7]/1.9 [1.7,2.2], 35.6 [29.9,46.9]/17.9 [16.3,19.9], and 213.6 [127.5,372.7]/140.4 [127.5,152.3] months, respectively). For Hispanic/Latino versus not Hispanic/Latino patients, survival estimates were 93.8% (91.0,95.8)/89.9% (88.8,90.9); freedom from all-cause hospitalization was 62.5% (57.6,67.0)/59.2% (57.4,60.9). Overall, safety profiles were similar between the groups and consistent with the known profile of macitentan.

conclusionsOPUS/OrPHeUS provides real-world insights into racial/ethnic minority groups receiving macitentan and other PAH-specific treatments in the USA. These data on treatment patterns and outcomes could help inform treatment decisions in the reported minority groups.

trial registrationOPsumit® Users Registry (OPUS), NCT02126943; Opsumit® Historical Users cohort (OrPHeUS), NCT03197688; www. CLINICALTRIALS: gov .

Indexed as

Hypertension, PulmonaryPulmonary Arterial HypertensionPyrimidinesSulfonamidesAdultAgedBlack or African AmericanFemaleHispanic or LatinoHumansMaleMiddle AgedProspective StudiesRegistriesTreatment OutcomeUnited StatesmacitentanPyrimidinesSulfonamidesBlack/African AmericanEthnicityHispanic/LatinoMacitentanPulmonary arterial hypertensionRaceReal-word evidence

Identifiers

PMID41258625
PMCPMC12858455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.